Teriflunomide attenuates immunopathological changes in the dark agouti rat model of experimental autoimmune encephalomyelitis.

Abstract

Teriflunomide is an oral disease-modifying therapy recently approved in several locations for relapsing-remitting multiple sclerosis. To gain insight into the effects of teriflunomide, immunocyte population changes were measured during progression of experimental autoimmune encephalomyelitis in Dark Agouti rats. Treatment with teriflunomide attenuated levels of spinal cord-infiltrating T cells, natural killer cells, macrophages, and neutrophils. Teriflunomide also mitigated the disease-induced changes in immune cell populations in the blood and spleen suggesting an inhibitory effect on pathogenic immune responses.

• Authors: Garth E Ringheim, Lan Lee, Lynn Laws-Ricker, Tomas Delohery, Li Liu, Donghui Zhang, Nicholas Colletti, Timothy J Soos, Kendra Schroeder, Barbara Fanelli, Nian Tian, Christopher W Arendt, Deborah Iglesias-Bregna, Margaret Petty, Zhongqi Ji, George Qian, Rajula Gaur, Daniel Weinstock, Jean Cavallo, Juventas Telsinskas, Kathleen McMonagle-Strucko
• Journal: Frontiers in neurology (Front Neurol) Vol. 4 Pg. 169 ( 2013) ISSN: 1664-2295 [Print] Switzerland
• PMID: 24198809 (Publication Type: Journal Article)